In 2020, Dr. Dent was a key voice in discussing the importance of biomarkers for Alzheimer’s disease with members of Congress. She participated in Capitol Hill briefings and attended multiple meetings with legislators to explain the issue. She is a powerful advocate for pioneering innovation and continues to be a trusted advisor and partner to Biogen’s Public Policy and Government Affairs team.
Dr. Gersham Dent
